they are kicking themselves for sure but this has hit so many radars that its only a matter of time imo

$MECK

MecklerMedia Corp

nice - slow and steady wins the race $MECK

My last post on the subject - the point i was making had nothing to do with the stock.

The point was focused on public opinion of businesses that should no longer be operating but still are.


Unfortunately comprehension skills lack here like ethics in pennies.

It's sad

My apologies if some lost money on those stocks or here.

$JCP

lol awww shucks $JCP

lol im not worried about my credit ability on a random chat board

in case you havent realized i picked the name futurebankruptcy to keep away from typical nonsense and people on here.

im not looking for followers
im not looking for credibility
im not looking for anyones approval or praise

whats your take on the after hours action?

$ARNA

nice day today up 3.5% $ARNA

huge reasons to accum - float approx 1Million - 1.9 Million max its starting to look like the available float is under 1 Million

$MECK

USA Commerce Daily on $ARNA "...add $2.33 or 164.08%..."

USA Commerce Daily on ARNA "...add $2.33 or 164.08%..."

probably their portfolio position lol $ARNA

"...price target of $3.75.....Strong Buy ..." Analyst’s Ratings: Arena Pharmaceuticals, Inc. $ARNA

http://standardoracle.com/2017/04/13/best-known-analysts-ratings-arena-pharmaceuticals-inc-arna-2/

rena Pharmaceuticals, Inc. (ARNA) lost -0.7% to reach $1.42 in the previous trading session. Overall, 1.03 Million shares exchanged hands versus its average trading volume of 1.77 Million shares. The relative volume of the stock is 0.58, while its market cap is $348.57 Million.

Relative Strength Index

The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements. The RSI oscillates between zero and 100. Usually the RSI is considered overbought when above 70 and oversold when less than 30.



Relative strength index (RSI-14) for Arena Pharmaceuticals, Inc. (ARNA) is at 45.8.

Price Target

A price target is the projected price level of a financial security stated by an investment analyst. It represents a security’s price that, if achieved, results in a trader recognizing the best possible outcome for his investment. This is the price at which the trader or investor wants to exit his existing position so he can realize the most reward.

Basically, a price target is an individual analyst’s projection on the future price of a stock. There is no concrete way to calculate a price target. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target.

Arena Pharmaceuticals, Inc. (ARNA) has been given an average price target of $3.75 from analysts, according to data collected by Finviz.

Earnings Forecast

Earnings per share (EPS) is the portion of a company’s profit allocated to each outstanding share of common stock. Earnings per share serves as an indicator of a company’s profitability. Consensus earnings estimates are far from perfect, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. Investors measure stock performance on the basis of a company’s earnings power. To make a proper assessment, investors seek a sound estimate of this year’s and next year’s earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.

Maximum and minimum EPS estimate for the current quarter is projected at $-0.02 and $-0.1, respectively, according to 6 analysts. Comparatively, Arena Pharmaceuticals, Inc. posted earnings of $0 per share in the same quarter last year.

The company is expected to report earnings of $-0.07 a share for the next quarter.

Revenue Estimate

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. It is the “top line” or “gross income” figure from which costs are subtracted to determine net income.

Arena Pharmaceuticals, Inc. (ARNA) is expected to post revenue of $8.35 Million in the current quarter, according to consensus of 6 analysts. The high and low revenue estimates for the current quarter are $24.35 Million and $3.1 Million, respectively. The company reported revenue of $0 in the same period last year.

Moving Averages

A moving average (MA) is a trend-following or lagging indicator because it is based on past prices. The average is taken over a specific period of time, like 10 days, 20 minutes, 30 weeks, or any time period the trader chooses. There are advantages to using a moving average in your trading, as well options on what type of moving average to use. Moving average strategies are also popular and can be tailored to any time frame, suiting both long term investors and short-term traders.

A moving average can help cut down the amount of “noise” on a price chart. Look at the direction of the moving average to get a basic idea of which way the price is moving. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range.

Arena Pharmaceuticals, Inc. (ARNA)’s distance from 200 day simple moving average is -9.08 percent, its distance from 50 day simple moving average is -4.68 percent, while its distance from 20 day simple moving average is -3.06 percent.

52-week High/Low

A 52-week high/low is the highest and lowest price that a stock has traded at during the previous year. Many traders and investors view the 52-week high or low as an important factor in determining a stock’s current value and predicting future price movement.

Arena Pharmaceuticals, Inc. (ARNA) has a 52-week high of $2.16 and a 52-week low of $1.34.

Analysts Recommendation

Arena Pharmaceuticals, Inc. (ARNA) has a mean recommendation of 2, according to data compiled by Zacks Investment Research. The recommendation scale measures the value from 1 to 5, where 1 means ‘’Strong Buy’’ and 5 stands for ”Sell”.

FBR & Co. Initiated its coverage for Arena Pharmaceuticals, Inc. (ARNA) in a note sent to investors on 15-Sep-16. The research firm Initiated the stock to Outperform. Moreover, RBC Capital Mkts issued Initiated rating for the stock on 23-Jan-15. WallachBeth also Initiated the company to Buy on 15-Nov-13, 2016. Additionally, Cowen Initiated its ratings on the stock to Market Perform.

Historical Trends

A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future. Trend analysis is based on historical data about the stock’s performance given the overall trends of the market and particular indicators within the market.

Arena Pharmaceuticals, Inc. shares increased 0.71 percent over the past week and rose 0 percent over the previous month. The stock climbed 0.71 percent over the past quarter, while declined -22.83 percent over the past six months.

"...price target of $3.75....Strong Buy Rating ..." Analyst’s Ratings: Arena Pharmaceuticals, Inc. $ARNA

http://standardoracle.com/2017/04/13/best-known-analysts-ratings-arena-pharmaceuticals-inc-arna-2/

rena Pharmaceuticals, Inc. (ARNA) lost -0.7% to reach $1.42 in the previous trading session. Overall, 1.03 Million shares exchanged hands versus its average trading volume of 1.77 Million shares. The relative volume of the stock is 0.58, while its market cap is $348.57 Million.

Relative Strength Index

The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements. The RSI oscillates between zero and 100. Usually the RSI is considered overbought when above 70 and oversold when less than 30.



Relative strength index (RSI-14) for Arena Pharmaceuticals, Inc. (ARNA) is at 45.8.

Price Target

A price target is the projected price level of a financial security stated by an investment analyst. It represents a security’s price that, if achieved, results in a trader recognizing the best possible outcome for his investment. This is the price at which the trader or investor wants to exit his existing position so he can realize the most reward.

Basically, a price target is an individual analyst’s projection on the future price of a stock. There is no concrete way to calculate a price target. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target.

Arena Pharmaceuticals, Inc. (ARNA) has been given an average price target of $3.75 from analysts, according to data collected by Finviz.

Earnings Forecast

Earnings per share (EPS) is the portion of a company’s profit allocated to each outstanding share of common stock. Earnings per share serves as an indicator of a company’s profitability. Consensus earnings estimates are far from perfect, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. Investors measure stock performance on the basis of a company’s earnings power. To make a proper assessment, investors seek a sound estimate of this year’s and next year’s earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.

Maximum and minimum EPS estimate for the current quarter is projected at $-0.02 and $-0.1, respectively, according to 6 analysts. Comparatively, Arena Pharmaceuticals, Inc. posted earnings of $0 per share in the same quarter last year.

The company is expected to report earnings of $-0.07 a share for the next quarter.

Revenue Estimate

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. It is the “top line” or “gross income” figure from which costs are subtracted to determine net income.

Arena Pharmaceuticals, Inc. (ARNA) is expected to post revenue of $8.35 Million in the current quarter, according to consensus of 6 analysts. The high and low revenue estimates for the current quarter are $24.35 Million and $3.1 Million, respectively. The company reported revenue of $0 in the same period last year.

Moving Averages

A moving average (MA) is a trend-following or lagging indicator because it is based on past prices. The average is taken over a specific period of time, like 10 days, 20 minutes, 30 weeks, or any time period the trader chooses. There are advantages to using a moving average in your trading, as well options on what type of moving average to use. Moving average strategies are also popular and can be tailored to any time frame, suiting both long term investors and short-term traders.

A moving average can help cut down the amount of “noise” on a price chart. Look at the direction of the moving average to get a basic idea of which way the price is moving. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range.

Arena Pharmaceuticals, Inc. (ARNA)’s distance from 200 day simple moving average is -9.08 percent, its distance from 50 day simple moving average is -4.68 percent, while its distance from 20 day simple moving average is -3.06 percent.

52-week High/Low

A 52-week high/low is the highest and lowest price that a stock has traded at during the previous year. Many traders and investors view the 52-week high or low as an important factor in determining a stock’s current value and predicting future price movement.

Arena Pharmaceuticals, Inc. (ARNA) has a 52-week high of $2.16 and a 52-week low of $1.34.

Analysts Recommendation

Arena Pharmaceuticals, Inc. (ARNA) has a mean recommendation of 2, according to data compiled by Zacks Investment Research. The recommendation scale measures the value from 1 to 5, where 1 means ‘’Strong Buy’’ and 5 stands for ”Sell”.

FBR & Co. Initiated its coverage for Arena Pharmaceuticals, Inc. (ARNA) in a note sent to investors on 15-Sep-16. The research firm Initiated the stock to Outperform. Moreover, RBC Capital Mkts issued Initiated rating for the stock on 23-Jan-15. WallachBeth also Initiated the company to Buy on 15-Nov-13, 2016. Additionally, Cowen Initiated its ratings on the stock to Market Perform.

Historical Trends

A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future. Trend analysis is based on historical data about the stock’s performance given the overall trends of the market and particular indicators within the market.

Arena Pharmaceuticals, Inc. shares increased 0.71 percent over the past week and rose 0 percent over the previous month. The stock climbed 0.71 percent over the past quarter, while declined -22.83 percent over the past six months.

hard to scoop these shares up $MECK

MecklerMedia Corp.

well i like the very sick pov

the comparison being ugly was precisely my intent/point

if they (RS and BN) survived it lends credence to the pov that $JCP is on the path to the up and up

Brick and Mortar stores arent dead is where im going with it $JCP

They said all my examples were dead bc of online, market, competition etc

and everyone was wrong

why

because people like to shop in stores just like they do online

this is a fippers paradise $USRM

cool is fickle and there are remeber RadioShack is suppose to be dead but they still have stores. Barnes and Nobles is suppose to be dead but they still have stores

$JCP

that is fantastic news!

welcome aboard friend - hope your ready for an amazing return on your investment.

6M O/S
Float 1.9 Million
Clean Books
$20M in NOL's ready for write off
CEO openly communicating with interest in sale/merger

and the 3-D printing market has boomed beyond belief. No reason to think the company may not be back soon.

3D Printing Titanium Parts Could Save Boeing Millions on Dreamliner Production

http://fortune.com/2017/04/11/3d-printing-norsk-boeing-dreamliner/

MECKLERMEDIA CORP. THE POTENTIAL IS HUGEEEEEE $MECK

Aerojet Rocketdyne Refines 3D Printing for Rocket Engines

http://www.engineering.com/3DPrinting/3DPrintingArticles/ArticleID/14722/Aerojet-Rocketdyne-Refines-3D-Printing-for-Rocket-Engines.aspx



MecklerMedia Corp. THE POTENTIAL IS HUGEEEEEEEE

$MECK

3D Printing Method Creates ‘Shape Shifting’ Objects

https://www.rdmag.com/article/2017/04/3d-printing-method-creates-shape-shifting-objects



MecklerMedia Corp. $MECK POtential Is HUGE!!!!!!!

A Mass-Market, 3D-Printed Athletic Shoe Is Coming, and This Upstart's Technology Is to Thank

https://www.fool.com/investing/2017/04/13/mass-market-3d-printed-athletic-shoe-is-coming.aspx



MecklerMedia Corp $MECK Potential is huge!

How do you build on Mars? 3D printing from dust!

https://www.cnet.com/news/3d-printing-for-the-moon-and-mars/
Let's say we get to Mars. Or ever decide to go back to the moon. It'll be far better to build everything we need using the resources available on location, rather than adding materials to the payload of the craft carrying us there.

The European Space Agency identified this in 2013, when it unveiled its plans for a 3D printed moon base, and architects have proposed 3D printing on Mars, too. And now we know it's possible, thanks to Northwestern University's Ramille Shah and her Tissue Engineering and Additive Manufacturing Laboratory.

The lab has created 3D printed objects out of Mars and Moon dust simulants, demonstrating that we could probably do the same with the real thing. The research has been published in the journal Scientific Reports.

The simulants are NASA-approved, and have similar compositions, particle shapes and particle sizes to the dust found on the Moon and on Mars. Shah's team mixed these dusts with solvents and biopolymers, then used a simple extrusion 3D printer to create a variety of objects, such as basic tools and Lego-like building blocks that can be assembled together.

These objects are over 90 percent dust, but they're also, the team said, flexible, elastic and tough, much like rubber. It can be cut, rolled, folded and shaped. The team is now working on a method of heating them in a kiln, making them into a hard, ceramic-like material.

MecklerMedia Corp $MECK Potential is huge!

you might be onto something - this fulx requires hair trigger day traiding protocol

$USRM

wowers today cliff dive is totally uncalled for - once people realize $JCP isnt going anywhere the value will return.

ill admit its making me think of scooping up for for the flip

the lower it goes the more that fight gets harder

A Formula 1 team is 3D printing race car parts

http://money.cnn.com/2017/04/11/technology/formula-1-3d-printing/index.html

Formula 1 race cars need to be constantly tweaked -- parts need to be replaced and swapped out to help cars perform at top speed.
But getting each of these specialized parts can take weeks. Now, one team is using 3D printing for an edge.
McLaren Racing Limited is using 3D printers to modify the parts on its race car. Replacing a rear wing took just a week and a half instead of the five weeks it would have taken with traditional methods.
"It's important to gain as many small improvements to the car's performance as quickly as we can," Neil Oatley, design and development director of McLaren Racing Limited told CNNTech. "If it allows us to bring a part to [the track] one race earlier or two races earlier, that's a gain that accumulates throughout the season and allows us to have a higher performance level."

McLaren is using about a dozen 3D printers from Stratasys, mostly in its office outside London. The team also travels to races with one. So far, they've used 3D printing to create more than 50 parts.

To replace the wing, the team designed and printed a new one out of plastic. The wing is next wrapped in carbon fiber. In the last step, the wing's plastic interior is dissolved, leaving the wing ready for racing.
Related: College students race pods in Hyperloop competition
The company's ultimate goal is to print parts out of carbon fiber, so that they can be immediately put on a car at the race site, according to Andy Middleton, a president at Stratasys.

Eventually, a 3D printer in the team's pit stop might deliver finished parts. The team's engineers could then even more rapidly create and experiment with parts. That would mean a lot more speed on the track, and perhaps, more victories.

is it believed that this may test 50-MA? Just trying to learn what i can. as i try and research some.

$USRM

i like that the base has been holding above 1.40 as opposed to the past when it would dip to 1.30

$ARNA

i flipped my triple down purchase to hedge my core position - $JCP

very smart position to take - MecklerMedia Corp is going to run hard $MECK

Addidas 3-D prints shoes. Potential for MecklerMedia Corp bounce back real.

http://money.cnn.com/2017/04/07/technology/adidas-3d-printed-shoe/index.html

$MECK

finally got in - now lets channel trade like mo-

$ARNA

everyone needs loving - my wallet likes pigs too. aint nobody saying no to bacon!

Merica

$JCP

If retail is dead why is Barnes and Nobles still around? JCP coming back as retail leader.

$JCP bouncing back strong

i would interpret it as already accounted for in the total

$MECK

there is good reason to be interested - the SS an Books are crazy clean and not many better options out there

$MECK

MEcklerMedia Corp. Rumor News

Fantastic action today as someone took a nice position $MECK

MecklerMedia Corp.

$JCP Back to 6.20+ tomorrow